Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p class="Inside-first-paragraph-drop-cap-" style="font-family:Arial, Helvetica, sans-serif; font-size:12pt;">The U.S. FDA approved a new human papillomavirus (HPV) vaccine in December of 2014.<sup>1</sup> Two HPV vaccines have been available for several years <span class="CharOverride-6">—</span> a bivalent vaccine (HP2) containing L1 protein of the oncogenic types 16 and 18 as well as a quadrivalent vaccine (HP4)containing type 16 and 18 together with types 6 and 11 (which cause genital warts). The Advisory Committee on Immunization Practices (ACIP) has recently updated their recommendations for the use of these vaccines: </p>

A New Expanded Human Papillomavirus Vaccine